JP2013505264A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505264A5 JP2013505264A5 JP2012529955A JP2012529955A JP2013505264A5 JP 2013505264 A5 JP2013505264 A5 JP 2013505264A5 JP 2012529955 A JP2012529955 A JP 2012529955A JP 2012529955 A JP2012529955 A JP 2012529955A JP 2013505264 A5 JP2013505264 A5 JP 2013505264A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- composition according
- cancer
- composition
- hepes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24346409P | 2009-09-17 | 2009-09-17 | |
| US61/243,464 | 2009-09-17 | ||
| PCT/US2010/049405 WO2011035212A2 (en) | 2009-09-17 | 2010-09-17 | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014231168A Division JP5974062B2 (ja) | 2009-09-17 | 2014-11-14 | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505264A JP2013505264A (ja) | 2013-02-14 |
| JP2013505264A5 true JP2013505264A5 (enExample) | 2013-09-26 |
Family
ID=43757159
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012529955A Pending JP2013505264A (ja) | 2009-09-17 | 2010-09-17 | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 |
| JP2014231168A Active JP5974062B2 (ja) | 2009-09-17 | 2014-11-14 | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 |
| JP2015024177A Pending JP2015129150A (ja) | 2009-09-17 | 2015-02-10 | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 |
| JP2016140167A Active JP6347807B2 (ja) | 2009-09-17 | 2016-07-15 | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014231168A Active JP5974062B2 (ja) | 2009-09-17 | 2014-11-14 | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 |
| JP2015024177A Pending JP2015129150A (ja) | 2009-09-17 | 2015-02-10 | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 |
| JP2016140167A Active JP6347807B2 (ja) | 2009-09-17 | 2016-07-15 | 疼痛制御及び脱髄損傷の回復におけるｎ−２−ヒドロキシ−エチル−ピペラジン−ｎ’−２−エタンスルホン酸（ｈｅｐｅｓ）の役割 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8883855B2 (enExample) |
| EP (3) | EP2477626A4 (enExample) |
| JP (4) | JP2013505264A (enExample) |
| KR (1) | KR101737775B1 (enExample) |
| CN (4) | CN107260740A (enExample) |
| AR (1) | AR078290A1 (enExample) |
| AU (1) | AU2010295445B2 (enExample) |
| BR (1) | BR112012006155A2 (enExample) |
| CA (3) | CA3122553A1 (enExample) |
| HK (1) | HK1199621A1 (enExample) |
| IL (2) | IL264055B2 (enExample) |
| IN (1) | IN2012DN02499A (enExample) |
| MX (2) | MX360190B (enExample) |
| MY (2) | MY174012A (enExample) |
| NZ (1) | NZ598861A (enExample) |
| SG (3) | SG179191A1 (enExample) |
| TW (2) | TWI494106B (enExample) |
| WO (1) | WO2011035212A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY174012A (en) * | 2009-09-17 | 2020-03-03 | Bespoke Bioscience Llc | Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
| CA2956919C (en) | 2014-07-21 | 2022-07-19 | Glia, Llc | Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids |
| CA2984379C (en) * | 2015-04-28 | 2024-06-11 | Newsouth Innovations Pty Limited | Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU641529B2 (en) * | 1990-07-30 | 1993-09-23 | Bloomfield D.A. | Zwitterionic compounds and their N-halo derivatives for use in the treatment of clinical conditions |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| WO1997002270A1 (de) | 1995-07-06 | 1997-01-23 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Thiolsilane, verfahren zu deren herstellung und deren verwendung |
| US5716959A (en) * | 1996-02-13 | 1998-02-10 | T. Ronald Theodore | Method of treating disease with piperazine zwitterion compounds |
| NZ550199A (en) * | 1998-02-11 | 2008-07-31 | Bellus Health Int Ltd | Treatment of inflammation, abeta-induced cell toxicity, neuronal cell death or neuronal cell loss in subjects suffering from alzheimer's disease |
| US9044478B2 (en) | 2004-11-10 | 2015-06-02 | Institut National De La Sante Et De La Recherche Medicale | Use of 1,4-bis (3-aminoalkyl) piperazine derivatives in the treatment of neurodegenerative diseases |
| JP2010532331A (ja) * | 2007-07-05 | 2010-10-07 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 抗痙攣医薬組成物 |
| EP2011491A1 (en) | 2007-07-05 | 2009-01-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anticonvulsive pharmaceutical compositions |
| EP2163246A1 (en) * | 2008-09-12 | 2010-03-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin |
| US8709299B2 (en) | 2009-09-04 | 2014-04-29 | Basf Se | Dye sensitised solar cell |
| AU2014206220B2 (en) | 2009-09-17 | 2016-09-29 | Bespoke Bioscience, Llc | Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
| MY174012A (en) | 2009-09-17 | 2020-03-03 | Bespoke Bioscience Llc | Role of n-2-hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury |
-
2010
- 2010-09-17 MY MYPI2015002505A patent/MY174012A/en unknown
- 2010-09-17 CN CN201710494640.6A patent/CN107260740A/zh active Pending
- 2010-09-17 CA CA3122553A patent/CA3122553A1/en active Pending
- 2010-09-17 JP JP2012529955A patent/JP2013505264A/ja active Pending
- 2010-09-17 MX MX2015008916A patent/MX360190B/es unknown
- 2010-09-17 EP EP10817952.4A patent/EP2477626A4/en not_active Withdrawn
- 2010-09-17 SG SG2012018842A patent/SG179191A1/en unknown
- 2010-09-17 CA CA2774375A patent/CA2774375C/en active Active
- 2010-09-17 AU AU2010295445A patent/AU2010295445B2/en active Active
- 2010-09-17 KR KR1020127009683A patent/KR101737775B1/ko active Active
- 2010-09-17 SG SG10201500510YA patent/SG10201500510YA/en unknown
- 2010-09-17 US US12/885,404 patent/US8883855B2/en active Active
- 2010-09-17 TW TW099131755A patent/TWI494106B/zh active
- 2010-09-17 WO PCT/US2010/049405 patent/WO2011035212A2/en not_active Ceased
- 2010-09-17 BR BR112012006155A patent/BR112012006155A2/pt not_active Application Discontinuation
- 2010-09-17 EP EP19161338.9A patent/EP3520794A3/en active Pending
- 2010-09-17 CN CN201811365002.5A patent/CN109224077A/zh active Pending
- 2010-09-17 SG SG10202100421XA patent/SG10202100421XA/en unknown
- 2010-09-17 IL IL264055A patent/IL264055B2/en unknown
- 2010-09-17 EP EP14191925.8A patent/EP2835133B1/en active Active
- 2010-09-17 MY MYPI2012001195A patent/MY159626A/en unknown
- 2010-09-17 AR ARP100103407A patent/AR078290A1/es unknown
- 2010-09-17 MX MX2012003212A patent/MX2012003212A/es active IP Right Grant
- 2010-09-17 CN CN201410166019.3A patent/CN103977405A/zh active Pending
- 2010-09-17 NZ NZ598861A patent/NZ598861A/xx unknown
- 2010-09-17 CN CN2010800521032A patent/CN102612366A/zh active Pending
- 2010-09-17 TW TW103124615A patent/TWI562777B/zh active
- 2010-09-17 CA CA2977918A patent/CA2977918C/en active Active
-
2012
- 2012-03-15 IL IL218677A patent/IL218677B/en active IP Right Grant
- 2012-03-22 IN IN2499DEN2012 patent/IN2012DN02499A/en unknown
-
2014
- 2014-09-09 US US14/481,582 patent/US9867820B2/en active Active
- 2014-11-14 JP JP2014231168A patent/JP5974062B2/ja active Active
-
2015
- 2015-01-06 HK HK15100074.2A patent/HK1199621A1/xx unknown
- 2015-02-10 JP JP2015024177A patent/JP2015129150A/ja active Pending
-
2016
- 2016-07-15 JP JP2016140167A patent/JP6347807B2/ja active Active
-
2017
- 2017-10-04 US US15/725,007 patent/US10213425B2/en active Active
-
2019
- 2019-01-14 US US16/247,233 patent/US20190142825A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hindmarch et al. | Cognition and depression: the effects of fluvoxamine, a sigma‐1 receptor agonist, reconsidered | |
| JP2010535801A5 (enExample) | ||
| JP5657556B2 (ja) | α７選択的リガンドを用いる治療 | |
| Cosci et al. | The monoamine hypothesis of depression revisited: could it mechanistically novel antidepressant strategies? | |
| RU2012140148A (ru) | (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения | |
| RU2018137496A (ru) | Органические соединения | |
| Inoue et al. | Bromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression | |
| NZ583192A (en) | Methods for treating dependence | |
| RU2016143357A (ru) | Органические соединения | |
| CA2341441A1 (en) | Methods of using and compositions comprising dopamine reuptake inhibitors | |
| JP2018512127A5 (enExample) | ||
| Das et al. | Neurotransmitter-based strategies for the treatment of cognitive dysfunction in Down syndrome | |
| JP2013505264A5 (enExample) | ||
| Reeves et al. | ICase Report | |
| CA2641659A1 (en) | 4-acylaminopyridine derivative mediated neurogenesis | |
| US20090005443A1 (en) | Treatment of Depression | |
| CA2511619A1 (en) | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders | |
| MX2008015887A (es) | Tratamiento de condiciones psicologicas utilizando antagonista m1 de receptor muscarinico. | |
| WO2004105690A2 (en) | Treatment of chronic pain associated with drug or radiation therapy | |
| JP2018508556A5 (enExample) | ||
| JP5634529B2 (ja) | 強迫性障害（ｏｃｄ）処置用の薬剤の製造のためのアゴメラチンの使用 | |
| JP2015187122A (ja) | ピロリジントリプル再取込み阻害剤 | |
| Lai | Escitalopram-related visual and auditory hallucination in a non-dementia patient with depression | |
| JPWO2020131899A5 (enExample) | ||
| JP5278308B2 (ja) | 糖尿病性神経障害の新規予防剤及び／又は治療剤 |